Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Loxapine
Drug ID BADD_D01326
Description An antipsychotic agent used in schizophrenia. [PubChem]
Indications and Usage For the management of the manifestations of psychotic disorders such as schizophrenia
Marketing Status approved
ATC Code N05AH01
DrugBank ID DB00408
KEGG ID D02340
MeSH ID D008152
PubChem ID 3964
TTD Drug ID D0U5OE
NDC Product Code 51097-001; 0527-1395; 50090-4701; 70518-0347; 0591-0369; 35573-436; 35573-438; 35573-439; 70518-1792; 0591-0370; 62135-492; 64850-892; 0591-0372; 0591-0371; 0527-1397; 70518-0416; 64850-890; 0527-1394; 0527-1396; 53296-0095; 62135-493; 70518-1681; 64850-891; 64850-893; 70518-0346; 70518-1896; 35573-437
UNII LER583670J
Synonyms Loxapine | 2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine | Oxilapine | Cloxazepine | Loxapine Hydrochloride | Hydrochloride, Loxapine | Loxitane | Loxapine Succinate | Succinate, Loxapine | Loxapinsuccinate | Loxipine Succinate | Loxipine Maleate | Maleate, Loxipine | CL-71,563 | CL 71,563 | CL71,563 | Loxapine Monohydrochloride
Chemical Information
Molecular Formula C18H18ClN3O
CAS Registry Number 1977-10-2
SMILES CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001---
Neuroleptic malignant syndrome08.05.01.005; 12.03.01.003; 15.05.04.015; 17.05.02.003---
Oculogyric crisis06.05.02.002; 17.01.03.002---
Oedema08.01.07.006; 14.05.06.010---
Orthostatic hypotension17.05.01.020; 24.06.03.004---
Palpitations02.11.04.012--
Paraesthesia17.02.06.005; 23.03.03.094--
Personality disorder19.05.02.002---
Photosensitivity reaction23.03.09.003--
Polydipsia05.03.03.002; 14.05.02.001---
Protrusion tongue07.14.02.002; 17.02.05.037---
Pruritus23.03.12.001--
Rash23.03.13.001---
Renal failure20.01.03.005---
Respiratory depression17.02.05.047; 22.02.01.010---
Salivary hypersecretion07.06.01.009---
Seborrhoea23.02.07.001---
Seborrhoeic dermatitis23.03.04.018---
Seizure17.12.03.001--
Sensory loss17.02.07.007---
Shock24.06.02.002---
Somnolence17.02.04.006; 19.02.05.003--
Stress19.06.02.004---
Swollen tongue07.14.02.003; 10.01.05.015; 23.04.01.014---
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tachycardia02.03.02.007---
Tardive dyskinesia17.01.02.012---
Tension19.06.02.005---
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages